FRANCE LAUNCH COMPASS · All indications · All regions · All facility types · All hub clusters · All institutions
Market & MRD Opportunity
Where is the MRD opportunity across the covered centres?
All indications · All regions · All facility types · All hub clusters · All institutions
Active treated patients
7,800
MM 4,560 · CLL 3,240
Annual newly diagnosed patients
1,990
10 covered institutions
CLL watch-and-wait patients
955
Binet A active surveillance
MRD-eligible testing opportunities
4,191
30 gate records · 5 hubs
Current decision-gate MRD tests
2,632
tests per year across 5 covered hubs
Eligible testing gap
1,559
eligible opportunities without a test each year
Coverage: epidemiology from 10 covered institutions · decision-gate funnel from 5 covered hubs. The two datasets cover different institutions and measure different things.
MRD decision-gate conversion
5 covered hubs · gate-level opportunities
- Gate 1: End of L1 Induction (Pre-ASCT)
- Gate 2: Post-ASCT (+100 Days Consolidation)
- Gate 3: Maintenance Checkpoints (12m / 24m Len +/- Dara)
- Gate 4: Relapse / L2-L3+ (Post CAR-T / Bispecific / Triplet)
- Gate 5: End of L1 Fixed-Duration (Ven+Obi 12m / Ibr+Ven 15m)
- Gate 6: Relapsed CLL L2+ & Continuous BTKi Stopping Trial Gate
Active treated patients by line of therapy and clinical profile
10 covered institutions
955 CLL watch-and-wait (untreated) patients — includes 95 recorded on spoke-centre L1 rows
Testing uptake
Using the observed routine and trial testing rate on each gate record.
Current annual tests
2,632
Estimated annual tests
2,632
Remaining eligible testing gap
1,559
Change from current
0
Institution epidemiology
48 records · 10 covered institutions
Institution
Line of therapy
48 of 48 records
| 750100018 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib | 60% | 65-79 yrs | 310 | 30% | 93 | |
| 750100018 | CLL | L2+ | Relapsed / Refractory CLL (L2/L3+) | Venetoclax + Rituximab / Non-Covalent BTKi | 59% | >=80 yrs | 270 | 65% | 176 | |
| 750100018 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd / Isa-VRd Lite | 53% | 65-79 yrs | 260 | 74% | 192 | |
| 590780193 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib | 60% | 65-79 yrs | 260 | 27% | 70 | |
| 310781406 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib / Ibrutinib mono | 60% | 65-79 yrs | 250 | 28% | 70 | |
| 750100018 | Multiple Myeloma (MM) | L1 | Transplant-Eligible (TE) | Quadruplet (Dara-VRd / Isa-VRd) + ASCT | 57% | <65 yrs | 250 | 85% | 213 | |
| 310781406 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Anti-CD38 Triplet/Doublet (Dara-Rd / Dara-VMP) | 53% | 65-79 yrs | 240 | 72% | 173 | |
| 750100018 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Carfilzomib / Pomalidomide | 55% | 65-79 yrs | 240 | 63% | 151 | |
| 590780193 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 52% | 65-79 yrs | 225 | 71% | 160 | |
| 590780193 | CLL | L2+ | Relapsed / Refractory CLL (L2/L3+) | Venetoclax + Rituximab / BTKi switch | 58% | >=80 yrs | 220 | 63% | 139 | |
| 310781406 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Dara-Kd /Pom-based | 54% | 65-79 yrs | 215 | 61% | 131 | |
| 310781406 | CLL | L2+ | Relapsed / Refractory CLL (L2/L3+) | Venetoclax + Rituximab / Covalent or Non-Covalent BTKi | 59% | >=80 yrs | 215 | 64% | 138 | |
| 440000289 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib | 59% | 65-79 yrs | 215 | 28% | 60 | |
| 310781406 | Multiple Myeloma (MM) | L1 | Transplant-Eligible (TE) | Quadruplet (Dara-VRd / Isa-VRd) + ASCT | 56% | <65 yrs | 210 | 84% | 176 | |
| 750100018 | Multiple Myeloma (MM) | L3+ | Triple-Class Exposed (CAR-T / Bispecific) | Cilta-cel / Ide-cel / Teclistamab / Talquetamab | 56% | 65-79 yrs | 210 | 68% | 143 | |
| 750100018 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab / Ibrutinib + Venetoclax | 63% | <65 yrs | 210 | 87% | 183 | |
| 440000289 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 53% | 65-79 yrs | 210 | 73% | 153 | |
| 590780193 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Dara-Pd | 54% | 65-79 yrs | 200 | 60% | 120 | |
| 130786049 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Anti-CD38 Doublet/Triplet (Dara-Rd) | 52% | 65-79 yrs | 195 | 70% | 137 | |
| 130786049 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib | 59% | 65-79 yrs | 195 | 26% | 51 | |
| 590780193 | Multiple Myeloma (MM) | L1 | Transplant-Eligible (TE) | Quadruplet (Dara-VRd / Isa-VRd) + ASCT | 55% | <65 yrs | 195 | 84% | 164 | |
| 440000289 | Multiple Myeloma (MM) | L1 | Transplant-Eligible (TE) | Quadruplet (Dara-VRd / Isa-VRd) + ASCT | 56% | <65 yrs | 185 | 85% | 157 | |
| 440000289 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Pom-based | 54% | 65-79 yrs | 185 | 61% | 113 | |
| 130786049 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Dara-Pd / Pom-based | 54% | 65-79 yrs | 180 | 59% | 106 | |
| 440000289 | CLL | L2+ | Relapsed / Refractory CLL (L2/L3+) | Venetoclax + Rituximab | 58% | >=80 yrs | 180 | 62% | 112 | |
| 310781406 | Multiple Myeloma (MM) | L3+ | Triple-Class Exposed (CAR-T / Bispecific) | Cilta-cel / Ide-cel / Teclistamab / Talquetamab | 55% | 65-79 yrs | 175 | 66% | 116 | |
| 130786049 | Multiple Myeloma (MM) | L1 | Transplant-Eligible (TE) | Quadruplet (Dara-VRd / Isa-VRd) + ASCT | 55% | <65 yrs | 175 | 82% | 144 | |
| 590780193 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab | 61% | <65 yrs | 170 | 85% | 145 | |
| 130786049 | CLL | L2+ | Relapsed / Refractory CLL (L2/L3+) | Venetoclax + Rituximab / Pirtobrutinib | 58% | >=80 yrs | 165 | 62% | 102 | |
| 590780193 | Multiple Myeloma (MM) | L3+ | Triple-Class Exposed (CAR-T / Bispecific) | Cilta-cel / Teclistamab / Elranatamab | 55% | 65-79 yrs | 160 | 65% | 104 | |
| 310781406 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab / Ibrutinib + Venetoclax | 62% | <65 yrs | 155 | 86% | 133 | |
| 440000289 | Multiple Myeloma (MM) | L3+ | Triple-Class Exposed (CAR-T / Bispecific) | Cilta-cel / Ide-cel / Teclistamab | 55% | 65-79 yrs | 150 | 66% | 99 | |
| 440000289 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab | 62% | <65 yrs | 145 | 85% | 123 | |
| 130786049 | Multiple Myeloma (MM) | L3+ | Triple-Class Exposed (CAR-T / Bispecific) | Cilta-cel / Teclistamab / Elranatamab | 56% | 65-79 yrs | 140 | 64% | 90 | |
| 130786049 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab | 61% | <65 yrs | 120 | 84% | 101 | |
| 830000088 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 52% | 65-79 yrs | 115 | 70% | 81 | |
| 840000055 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 53% | 65-79 yrs | 105 | 70% | 74 | |
| 310012455 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 54% | 65-79 yrs | 95 | 71% | 67 | |
| 820000018 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd | 53% | 65-79 yrs | 75 | 69% | 52 | |
| 810000042 | Multiple Myeloma (MM) | L1 | Transplant-Ineligible (TNE) | Dara-Rd (Local Day Hospital) | 52% | 65-79 yrs | 65 | 68% | 44 | |
| 310012455 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab | 60% | 65-79 yrs | 65 | 82% | 53 | |
| 810000042 | CLL | L1 | Continuous Oral BTKi CLL | Acalabrutinib / Zanubrutinib | 60% | 65-79 yrs | 60 | 25% | 15 | |
| 820000018 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Isa-Kd / Pom-based | 54% | 65-79 yrs | 55 | 56% | 31 | |
| 810000042 | Multiple Myeloma (MM) | L2 | Relapsed / Refractory L2 | Dara-Pd / Isa-Kd | 51% | >=80 yrs | 50 | 54% | 27 | |
| 810000042 | CLL | L1 | Fixed-Duration CLL | Venetoclax + Obinutuzumab | 61% | 65-79 yrs | 35 | 80% | 28 | |
| 310781406 | CLL | Watch & Wait | Untreated / Active Surveillance (Binet A) | No Active Drug (Watch & Wait) | 61% | 65-79 yrs | 0 | 0% | 0 | |
| 130786049 | CLL | Watch & Wait | Untreated / Active Surveillance (Binet A) | No Active Drug (Watch & Wait) | 60% | 65-79 yrs | 0 | 0% | 0 | |
| 750100018 | CLL | Watch & Wait | Untreated / Active Surveillance (Binet A) | No Active Drug (Watch & Wait) | 62% | 65-79 yrs | 0 | 0% | 0 |